ASAP3 deficiency alleviates hepatic senescence and correlates with extended healthspan in mice.
Key claim: ASAP3 deficiency extends lifespan and healthspan in mice by alleviating hepatic senescence through restored actin cytoskeleton dynamics, enhanced autophagy, and improved mitochondrial function.
Abstract
The aging liver not only declines in function but also accelerates systemic aging and shortens lifespan. Identifying key molecular targets to delay liver aging is important for promoting health and longevity. ASAP3 is involved in cytoskeletal remodeling, but its role in aging remains unexplored. Here, we found that ASAP3 expression was upregulated in aged mouse livers and HOinduced AML12 cells. In AML12 hepatocytes, ASAP3 knockdown attenuated HO-induced senescence, enhanced autophagic flux, reduced mitochondrial ROS, and restored mitochondrial membrane potential, whereas ASAP3 overexpression had opposite effects. Phalloidin staining and Western blot analysis showed that ASAP3 knockdown significantly reduced the abnormal accumulation of F-actin and F-actin/G-actin ratio, while ASAP3 overexpression aggravated F-actin accumulation, and increased F-actin/G-actin ratio in AML12 cells. In addition, inhibition of autophagy abolished the alleviating effect of ASAP3 knockdown on senescence, whereas enhancing autophagy protected against cellular senescence induced by ASAP3 overexpression. Furthermore, disruption of F-actin assembly with cytochalasin D rescued the suppression of autophagic flux caused by ASAP3 overexpression. In vivo, ASAP3 knockout extended lifespan, improved cognitive and motor functions, and remodeled systemic metabolism in both sexes. ASAP3 knockout mice also showed reduced senescence phenotype, maintained F-actin structure, and enhanced autophagic flux in the liver. Furthermore, serum lipidomics revealed significant enrichment of pathways related to actin cytoskeleton regulation, autophagy, and primary bile acid biosynthesis in Asap3mice. Collectively, these findings demonstrate that ASAP3 is a novel regulator of liver aging, promoting senescence and impairing autophagy and mitochondrial function by disrupting actin cytoskeleton dynamics. Targeting ASAP3 may represent a promising strategy to delay hepatic aging and extend healthspan.
Why this matters
This is the first mouse-genetic entry point positioning ASAP3 as a coordinating node where actin cytoskeletal dynamics, autophagic flux, and mitochondrial quality control converge on hepatic senescence — moving the actin–proteostasis–mitochondria linkage from review-level speculation to a lifespan-extending knockout in a mammal. It slots into the vault’s growing catalog of specific upstream regulators (PRMT6/FOXG1, METTL13/Foxa1, BCAP31/POLR1E) that couple a single gene to a tissue-specific senescence program with organismal readouts. Translation remains distant: all data are mouse/cell, ASAP3 has no human clinical narrative yet, and the hepatic phenotype has not been benchmarked against existing autophagy- or senolytic-directed interventions.